Regeneron is investing in external innovation by acquiring research and development assets, resulting in a $19 million charge. This strategic move to bolster its drug pipeline may create needs for R&D data integration, clinical trial management solutions, or new research technologies to support the acquired assets.
Filing excerpt
The Company currently expects that its financial results calculated in accordance with U.S. generally accepted accounting principles (“GAAP”) and its non-GAAP financial results for the fourth quarter 2025 will include an acquired in-process research and development (“IPR&D”) charge of approximately $19 million on a pre-tax basis.
What this signalsIntegration work after a deal often opens needs for new systems and services.
Vendors
Regions named
sec-8kacquisitionAnnouncedGet every 8-K signal for Regeneron and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Regeneron this week?”
The Signal API returns 8-K signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-8k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/0468a457-a01d-43c7-8789-8e08ed113227 returns this record as JSON. POST /v1/companies/enrich returns every signal for regeneron.com.
{
"signal_id": "0468a457-a01d-43c7-8789-8e08ed113227",
"signal_type": "sec-8k",
"signal_subtype": "acquisitionAnnounced",
"detected_at": "2026-02-03T13:11:30.539+00:00",
"company": {
"name": "Regeneron",
"domain": "regeneron.com"
},
"data": {
"detail": "Regeneron is investing in external innovation by acquiring research and development assets, resulting in a $19 million charge. This strategic move to bolster its drug pipeline may create needs for R&D data integration, clinical trial management solutions, or new research technologies to support the acquired assets.",
"metrics": {
"timeframe": "current_quarter",
"dollar_context": "Acquired in-process research and development (IPR&D) charge",
"dollar_millions": 19
},
"summary": "Regeneron to record $19M charge for acquired in-process R&D in Q4 2025",
"excerpts": "The Company currently expects that its financial results calculated in accordance with U.S. generally accepted accounting principles (“GAAP”) and its non-GAAP financial results for the fourth quarter 2025 will include an acquired in-process research and development (“IPR&D”) charge of approximately $19 million on a pre-tax basis.",
"relevance": 0.8,
"sentiment": "neutral",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/872589/000110465926002691/tm262861d1_8k.htm",
"filing_date": "2026-01-12",
"filing_year": 2026,
"sales_relevance": "Integration needs coming",
"signal_category": "strategic",
"regions_mentioned": [
"UNITED STATES"
],
"vendors_mentioned": [
"J.P. Morgan"
]
}
}
curl https://signals.autobound.ai/v1/signals/0468a457-a01d-43c7-8789-8e08ed113227 \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"regeneron.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.